Application 761055
- Type
- BLA
- Sponsor
- REGENERON PHARMACEUTICALS
Application Products#
Product, Drug, Ingredient table| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|
| 001 | DUPIXENT | DUPILUMAB | INJECTABLE; INJECTION | 150MG/ML | No | No |
NDC Listings For This Application#
NDC, Name, Nonproprietary name table| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5911 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5914 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5915 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5916 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5918 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |
| 0024-5919 | Dupixent | Dupilumab | sanofi-aventis U.S. LLC | BLA | Current |